![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
March 31, 2021
The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
- Filter by
- Categories
- Tags
- Authors
- Show all
- All
- Active Clinical Trials
- From the Co-Chairs
- Institution Spotlights
- News in Brief
- People
- Special Topics
- Trial Results
- All
- AACR
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia
- Acute myeloid leukemia (AML)
- Adolescents and young adults
- Advanced melanoma
- Advanced practice providers
- Advocacy
- Anal cancer
- ARPA-H
- ASCO
- Awards
- AYA cancer
- Big data
- Bladder cancer
- Blood cancer
- Blood cancers
- Brain cancer
- Breast cancer
- Cancer
- Cancer care delivery research
- Cancer control
- Cancer research
- Cancer research policy
- Cancer screening
- Cancer surveillance
- Cardiotoxicity
- Chemoimmunotherapy
- Chemotherapy
- Chronic lymphocytic leukemia
- Chronic myelogenous leukemia
- Chronic myeloid leukemia
- Clinical trial
- Clinical trials
- Colorectal cancer
- Colorectal liver metastases
- ComboMATCH
- Comis Symposium
- Communication
- Community oncology
- Correlative science
- COVID-19
- Data science
- De-escalation
- Deep learning
- DEI
- Developmental therapeutics
- Diversity
- EGFR
- Esophagus cancer
- Ethics
- Financial hardship
- Gallbladder cancer
- Gastric cancer
- Gastroesophageal junction cancer
- GBM
- Gender equity
- Genetic testing
- Genomics
- Geriatric oncology
- GI cancer
- Glioblastoma
- GM-CSF
- Green tea catechins
- Group Meeting
- GU cancer
- Head and neck cancer
- Head and neck squamous cell carcinoma
- health care
- Health care administration
- Health equity
- Hepatic arterial infusion
- HER2-positive breast cancer
- hormone therapy
- Imaging
- Immunotherapy
- In memory
- Institution Evaluation
- Just-in-time clinical trials
- Kidney cancer
- Language
- Leadership
- Leukemia
- Liver cancer
- Lung cancer
- Lung inflammation
- Lymphoma
- Mammography
- Meetings
- Melanoma
- Mentorship
- Mesothelioma
- Multiple myeloma
- Myelodysplastic neoplasms
- Myelodysplastic syndromes
- Myeloid malignancies
- Myeloma
- myeloMATCH
- National Cancer Act
- Natural language processing
- NCI
- NCI-Designated Comprehensive Cancer Centers
- NCI-MATCH
- NCORP
- Neuroendocrine tumors
- Non-small cell lung cancer
- NSCLC
- Older adults
- Ovarian cancer
- Pancreatic cancer
- Pancreatic cyst
- Pancreatic cysts
- Pancreatic NETs
- Pathology
- Patient-reported outcomes
- Penile cancer
- Peripheral neuropathy
- Personalized medicine
- Personalized screening
- Pneumonitis
- Policy
- Pragmatic clinical trials
- Precision medicine
- Prevention
- Prostate cancer
- Proteasome inhibitors
- Public-private partnerships
- Racism
- Radiation
- Radiology
- Rare disease
- Real-world data
- Recurrence
- Renal cell
- Renal cell carcinoma
- Reproductive health
- Research results
- Retroperitoneal sarcoma
- Sarcoma
- Scholarship
- Sexuality
- Side effects
- Smoking cessation
- Smoldering multiple myeloma
- Social determinants of health
- Social genomics
- Stomach cancer
- Survivorship
- Symptom control
- Symptom management
- Symptom science
- Targeted therapy
- Throat cancer
- Thyroid cancer
- TMIST
- Tobacco cessation
- Translational research
- Urinary tract cancer
- Vaccination
- Women in oncology
- Young investigators